Business context and reporting period
The supplied filing is Predictive Oncology Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2023, not a filing identified as Axe Compute Inc. Predictive Oncology focuses on applying AI and a biobank of more than 150,000 tumor samples to cancer drug development, alongside Birmingham contract research and Eagan medical-device operations. The company says it is concentrating resources on its AI-enabled oncology business. Share and per-share figures reflect the April 2023 1-for-20 reverse stock split.
Key financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $490,110 | $371,591 | $730,005 | $686,159 |
| Gross profit | $330,349 | $237,516 | $450,105 | $442,641 |
| Gross margin | 67% | 64% | 62% | 65% |
| Operating loss | $3,959,228 | $10,525,408 | $7,424,211 | $13,939,472 |
| Net loss | $3,923,368 | $10,391,324 | $7,345,170 | $13,762,039 |
| Net loss per share, basic and diluted | $0.98 | $2.89 | $1.84 | $4.00 |
At June 30, 2023, cash and equivalents were $14.76 million, down from $22.07 million at year-end 2022 and $28.25 million at June 30, 2022. Current assets were $15.97 million and current liabilities $3.76 million. The company reported no outstanding debt; operating lease liabilities totaled $2.96 million, including current and noncurrent amounts. Stockholders’ equity was $14.71 million, and accumulated deficit was $161.12 million.
For the first six months, operating cash use was $7.00 million, investing cash use was $306,000, and financing cash flow was zero. The comparable 2022 period used $6.43 million in operations and received $6.74 million from financing. Research and development expense was $68,171 for the 2023 first half.
Changes versus the prior comparable period
- Q2 revenue rose about 32% year over year; first-half revenue rose about 6%. Q2 sales included 7 STREAMWAY units versus 2 a year earlier; first-half unit sales were 7 versus 5.
- First-half gross margin declined to 62% from 65%; management attributed lower STREAMWAY margins primarily to product mix and lower-margin hardware sales.
- First-half net loss narrowed by about $6.42 million. The prior-year period included a $7.23 million goodwill impairment; the 2023 period instead included a $162,905 impairment of Birmingham property and equipment.
- Operating cash use increased by about $574,000 year over year, which management attributed primarily to higher operating expenses and working-capital changes. No financing proceeds were recorded in the 2023 first half.
- General and administrative and sales and marketing expenses increased. The filing attributes increases to items including investor-relations costs related to the reverse split, rent, and added sales and marketing staff.
Outlook, risks and unusual items
- Management believes existing capital resources can support the operating plan for 12 months after the financial statements were issued. It cautions that actual cash needs may differ and that future financing, if needed, may not be available on acceptable terms. The company has a history of losses and negative operating cash flow.
- The filing gives no quantified revenue, earnings, or cash-flow guidance. Management says it may pursue cost reductions or additional debt, equity, or other financing.
- The company recorded a $162,905 impairment for Birmingham property and equipment after projected cash flows changed. It also entered new Pittsburgh office and laboratory leases with approximately five-year terms in January 2023.
- The March 2023 Cancer Research Horizons collaboration provides for a share of specified commercialization revenue; no revenue had been recognized under it as of June 30, 2023.
- Risks include whether AI predictions and datasets prove reliable and commercially useful, evolving AI regulation, ability to attract collaborators and generate revenue, competition, intellectual-property and regulatory risks, macroeconomic disruption, and possible future financing needs.
- Disclosure controls and procedures were deemed ineffective at June 30, 2023 because of a continuing material weakness involving insufficient accounting resources to address complex transactions. The company added accounting staff and conducted remediation testing but had not concluded the weakness was fully remediated.
- Management reported no pending legal proceedings likely to have a material adverse effect. The filing notes that ordinary-course claims may arise.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing names Predictive Oncology Inc. (POAI), despite the request metadata naming Axe Compute Inc.
- Assess cash runway against the reported $7.00 million first-half operating cash use and management’s 12-month sufficiency statement.
- Track revenue growth and segment performance, particularly the AI-related Pittsburgh business, which reported $24,471 of first-half revenue and a $2.75 million segment loss.
- Monitor whether the Birmingham impairment signals further deterioration and whether the stated margin pressures persist.
- Check whether the internal-control material weakness is subsequently remediated and whether additional financing or dilution becomes necessary.